So far, we’ve learned of the following upcoming webinars with panels analyzing the implications of Wyeth v. Levine:

On Friday, March 27, at noon Eastern, the Defense Research Institute presents “Supreme Court’s Preemption Decision in Wyeth v. Levine,” featuring Michael Davis and Rebecca Wood (both of Sidley Austin), who wrote an amicus brief in Levine on behalf of DRI.

On April 1, at 1 p.m. Eastern, the Practicing Law Institute offers “Wyeth v. Levine: Supreme Court Rules on Implied Conflict Preemption for Prescription Drugs,” in which Russell Jackson (of Skadden Arps) will host a discussion featuring David Frederick (of Kellogg Huber), who argued for Levine in the Supreme Court, and Bert Rein (of Wiley Rein), who was on the defense team for Wyeth. That’s a great panel.

On April 8, at 1 p.m. Eastern, Strafford offers “Federal Preemption After Wyeth v. Levine,” featuring Scott Angstreich (of Kellogg Huber), who worked on the briefs for Levine, and Russell Jackson again. Russell must be making a career of talking about the case.

Finally, on April 15, at 11:30 a.m. Eastern, the Center for Business Intelligence presents “Buried Treasure: Preemption After Wyeth v. Levine,” with Rob Weiner (of Arnold & Porter) and our own Herrmann. Well — at least Weiner’s okay.

UPDATE: We just learned about another one. On March 24, at 1:30 p.m. Eastern, FDA News presents “The Real Impact of Wyeth v. Levine: How to Survive in a Post-Preemption World,” with Kurt Karst and John Fleder, both of Hyman, Phelps & McNamara.